U.S. Renal Care Presents Vadadustat Safety Analysis at Kidney Week
U.S. Renal Care presented an analysis of the VOICE trial comparing vadadustat with an ESA during a late-breaking session at American Society of Nephrology Kidney Week.
Story updates
01:23:41 PM UTC
SquawkNews
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patient
01:23:45 PM UTC
SquawkNews
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimenWALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. NASDAQ:AKBA, a biopharmaceutical company with the purpose to better the…
01:25:25 PM UTC
SquawkNews
Akebia’s Vadadustat Lowers Hospitalization Rate 10% Versus ESA in VOICE Trial Akebia Therapeutic